Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Clinical trial NCT07101159 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07101159
Sponsor: Fujian Cancer Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Early Breast Cancer Adjuvant Therapy Hormone Receptor Positive / HER2-negative Breast Cancer

Start date: 2025-09-01
Primary completion: 2031-12-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.